Loading chat...
US HB7871
Bill
Status
Introduced
3/9/2026
Primary Sponsor
Brett Guthrie
Click for details
AI Summary
- Codifies value-based purchasing arrangements in Medicaid, allowing manufacturers to report multiple best price points for a single drug dosage when the arrangement is offered to all states
- Excludes refunds, rebates, and payment reductions triggered by patients failing to achieve defined health outcomes from average manufacturer price calculations under value-based arrangements
- Requires HHS to issue guidance within 180 days on value-based purchasing for inpatient drugs, including multi-state agreements that allow fund transfers when patients receive treatment outside their home state
- Creates an anti-kickback statute exception for manufacturer remuneration to states under value-based purchasing arrangements when patients fail to meet outcome measures
- Mandates a GAO study by June 30, 2029, examining how value-based arrangements affect patient access to transformative therapies, health disparities, Medicaid expenditures, and long-term state savings
Legislative Description
MVP Act Medicaid VBPs for Patients Act
Health
Last Action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
3/9/2026
Committee Referrals
Energy And Commerce3/9/2026
Full Bill Text
No bill text available